Anzeige
Mehr »
Montag, 11.08.2025 - Börsentäglich über 12.000 News
Desert Gold: Zahlen untermauern das Potential
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PWSL | ISIN: US74365A3095 | Ticker-Symbol: PBDA
Tradegate
08.08.25 | 17:56
1,310 Euro
-0,76 % -0,010
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PROTALIX BIOTHERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PROTALIX BIOTHERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,3701,41021:02
1,3701,41020:29

Aktuelle News zur PROTALIX BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
01.08.Protalix BioTherapeutics, Inc. - 8-K, Current Report2
21.07.Protalix BioTherapeutics Names SVP and CFO1
21.07.Protalix BioTherapeutics, Inc. - 8-K, Current Report3
PROTALIX BIOTHERAPEUTICS Aktie jetzt für 0€ handeln
21.07.Führungswechsel im Finanzressort: Protalix BioTherapeutics ernennt Gilad Mamlok zum CFO1
21.07.Protalix BioTherapeutics appoints Gilad Mamlok as CFO1
21.07.Protalix Biotherapeutics Inc.: Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer395CARMIEL, Israel, July 21, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production...
► Artikel lesen
26.06.Protalix BioTherapeutics, Inc. - 8-K, Current Report4
09.05.Protalix BioTherapeutics targets phase 2 launch for PRX-115 in H2 202513
09.05.Protalix BioTherapeutics Inc. Q1 Loss Narrows476JERUSALEM (dpa-AFX) - Protalix BioTherapeutics Inc. (PLX) released Loss for first quarter of -$3.62 millionThe company's earnings came in at -$3.62 million, or -$0.05 per share. This compares...
► Artikel lesen
09.05.Protalix BioTherapeutics GAAP EPS of -$0.05 misses by $0.13, revenue of $10.11M misses by $11.49M6
09.05.Protalix BioTherapeutics, Inc. - 10-Q, Quarterly Report9
09.05.Protalix BioTherapeutics, Inc. - 8-K, Current Report11
09.05.Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results560Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, May 9, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:...
► Artikel lesen
08.05.Uncovering Potential: Protalix BioTherapeutics' Earnings Preview14
08.05.Protalix BioTherapeutics Q1 Earnings Preview2
23.04.Protalix BioTherapeutics, Inc. - 8-K, Current Report7
17.03.Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond13
17.03.Amended: Protalix Annual Earnings Fall489JERUSALEM (dpa-AFX) - (Amended: Recasting the story to correct the period, revenue)Protalix BioTherapeutics, Inc. (PLX), a biopharmaceutical company, Monday reported a decline in earnings for...
► Artikel lesen
17.03.Protalix plans Phase 2 for PRX-115 in H2 2025, projects higher royalty revenues by 20305
17.03.Protalix Q4 Earnings Fall, Stock Up In Pre-market319JERUSALEM (dpa-AFX) - Protalix BioTherapeutics, Inc. (PLX), a biopharmaceutical company, Monday announced that net income declined in the fourth quarter compared with last year. Shares of Protalix...
► Artikel lesen
Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1